- Growing
interest in the company’s innovative DehydraTECH™ drug delivery platform
from large global corporations
- Lexaria’s
strategy to be listed on a nationally recognized U.S. exchange will help
the company access a significantly larger audience of investors
- Lexaria
has 16 patents with another 60 pending worldwide and is the only company
to hold a patent for improved delivery of all non-psychoactive
cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms, has achieved virtually everything it set
out to do in 2019 and has even bigger plans for 2020 that include achieving
higher revenue and being listed on a major U.S. exchange, according to CEO
Chris Bunka in a strategic update to shareholders (http://ibn.fm/zA8bd). While its
shares remain “dramatically undervalued” at the moment, Bunka said, the company
boasts a successful 2019 during which it signed different partnerships and
agreements for use of its innovative DehydraTECH™ drug delivery platform.
The revolutionary drug delivery platform accelerates human
intestinal cell absorption of bioactive substances administered without the
need for inhalational dosing, co-administration with sugars or sweeteners, and
other unhealthy practices. It is applicable to a wide variety of bioactive
substances, including cannabis and nicotine. The innovative technology makes it
possible to deliver bioactive substances via oral ingestion bypassing
potentially unhealthy and unsafe practices. It has been shown to accelerate
CBD absorption by 499 percent and achieve a CBD blood concentration 319 percent
higher than traditional formulation.
The company developed its platform based on recognition of
the fact that inhalation poses certain risks. Edible ingestion makes it possible
to absorb a substance in a healthier and safer way. The platform has also been
proven to deliver up to 10 times more of active ingredients in comparison to
traditional edibles. DehydraTECH™ is the first platform of its kind that allows
users to access the primary benefits of inhalation – speed and efficiency –
while circumventing the risks of inhalation.
Lexaria Bioscience currently has 16 patents granted and more
than 60 patent applications worldwide and is the only company to hold a patent
for improved delivery of all cannabinoids and nicotine. According to Bunka, one
of the company’s biggest achievements in 2019 was receiving the first ever
patents to use DehydraTECH™ with cannabinoids for the treatment of Alzheimer’s,
Parkinson’s, schizophrenia and heart disease, in Australia. Lexaria is working
to gain fast-track patent status for the same health conditions in the U.S.
this year, which will allow the company to achieve one of its goals for 2020 –
developing relationships in the pharmaceutical industry, as well.
In 2019, the company also finalized a new contractual
relationship with a GMP-certified, FDA registered production company to get
enhanced DehydraTECH™ powders to market in the U.S. with current capacity of
roughly 200,000 servings per day. According to Bunka, this can increase to
400,000 servings per day within the same facility. “Lexaria is experiencing
strong demand from many companies requesting pre-processed DehydraTECH-enhanced
bulk powders for their specific product lines and with this facility, we can
meet that demand,” he said in a news release.
In 2020, the company expects to more than double its entire
2019 revenue from existing clients in the context of a projected sustainable
revenue growth all throughout the year and beyond by leveraging a rich pipeline
of prospective additional clients to be onboarded the following months, Bunka
explained. “One of our existing U.S. clients is embarking on an aggressive
growth strategy from their home state to several additional states within the next
year. Another existing U.S. client is in the next 90 days launching their
bottled beverage with CBD and DehydraTECH technology within, generating
first-ever revenue for Lexaria during Q1,” Bunka continued.
This revenue increase will support the company’s own future
growth plans. To increase its market visibility and ultimately expand its
customer base, Lexaria Bioscience plans to dramatically alter its capital
markets strategy this year to qualify for listing on a nationally recognized
U.S. exchange. The company has already met with several Wall Street investment
banking firms for this purpose. Listing on a major U.S. exchange would allow
Lexaria Bioscience access to a significantly larger audience of investors and
open a path to a growing number of more lucrative strategic opportunities,
Bunka concluded.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
